Hedley Rees collaborates with TrialSite News on supply chain challenges for cell & gene therapies
Analysts and inveastors need to know!
Pleased to report
I’m pleased to report that I’m working with Daniel O’Connor, CEO of TrialSite News, in educating financial analysts and investors in the challenges and risks associated with cell & gene therapies.
UK & European Cell & Gene Therapy Biotech
In assessing the “Trifecta” capacity and capability of European cell and gene therapy biotech, TrialSite collaborates with a network of experts including Hedley Rees, author and seasoned biopharma manufacturing executive. Rees is managing consultant at PharmaFlow Limited, a UK-based consultancy specializing in operations and supply chain management within life science.
Rees recently commented on a TrialSite article on Leucid Bio, and its approval by the UK MHRA to enter human trials with its CAR-T therapy using its proprietary Lateral CAR platform.